Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think?

O'Leary ST, Suh CA, Marin M; Vaccine Policy Collaborative Initiative.

Vaccine. 2012 Nov 6;30(48):6731-3. doi: 10.1016/j.vaccine.2012.08.075. Epub 2012 Sep 10.

PMID:
22975026
2.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.

3.

Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.

Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, Baxter R, Hambidge S, Nordin J, Naleway A, Belongia EA, Lieu T, Baggs J, Weintraub E; Vaccine Safety Datalink.

Pediatrics. 2010 Jul;126(1):e1-8. doi: 10.1542/peds.2010-0665. Epub 2010 Jun 29.

PMID:
20587679
4.

Safety of measles-containing vaccines in 1-year-old children.

Klein NP, Lewis E, Fireman B, Hambidge SJ, Naleway A, Nelson JC, Belongia EA, Yih WK, Nordin JD, Hechter RC, Weintraub E, Baxter R.

Pediatrics. 2015 Feb;135(2):e321-9. doi: 10.1542/peds.2014-1822. Epub 2015 Jan 5.

5.

Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.

Committee on Infectious Diseases.

Pediatrics. 2011 Sep;128(3):630-2. doi: 10.1542/peds.2011-1968. Epub 2011 Aug 28.

PMID:
21873692
6.

Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.

Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Morb Mortal Wkly Rep. 2008 Mar 14;57(10):258-60.

7.

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P.

Pediatr Infect Dis J. 2006 Jan;25(1):12-8.

PMID:
16395096
8.

Measles-containing vaccines and febrile seizures in children age 4 to 6 years.

Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, Jackson LA, Nordin J, Lieu T, Belongia EA, Fireman B.

Pediatrics. 2012 May;129(5):809-14. doi: 10.1542/peds.2011-3198. Epub 2012 Apr 2.

PMID:
22473362
9.

Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.

Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E.

Vaccine. 2014 Feb 3;32(6):645-50. doi: 10.1016/j.vaccine.2013.12.011. Epub 2013 Dec 25.

PMID:
24374498
10.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
11.

Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.

Macartney K, Gidding HF, Trinh L, Wang H, Dey A, Hull B, Orr K, McRae J, Richmond P, Gold M, Crawford N, Kynaston JA, McIntyre P, Wood N; Paediatric Active Enhanced Disease Surveillance Network.

JAMA Pediatr. 2017 Oct 1;171(10):992-998. doi: 10.1001/jamapediatrics.2017.1965.

PMID:
28806450
12.
13.

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Jul;25(7):615-22.

PMID:
16804432
14.

Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.

Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22. Erratum in: Pediatr Infect Dis J. 2013 Apr;32(4):e163.

PMID:
18600190
15.

Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.

Leung JH, Hirai HW, Tsoi KK.

Expert Rev Vaccines. 2015;14(8):1149-57. doi: 10.1586/14760584.2015.1057572. Epub 2015 Jun 16.

PMID:
26081133
16.
18.

Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.

Jacobsen SJ, Ackerson BK, Sy LS, Tran TN, Jones TL, Yao JF, Xie F, Cheetham TC, Saddier P.

Vaccine. 2009 Jul 23;27(34):4656-61. doi: 10.1016/j.vaccine.2009.05.056. Epub 2009 Jun 9.

PMID:
19520201
19.

A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzuela R, Stek JE, Helmond FA.

Hum Vaccin Immunother. 2016 Aug 2;12(8):2188-2196. Epub 2016 May 5.

20.

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.

Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O.

BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202.

Supplemental Content

Support Center